Professor Frank Barry, Regenerative Medicine Institute at University College Galway, Ireland, Zoobiquity Conference

Frank Barry, PhD
Professor of Cellular Therapy
Regenerative Medicine Institute (REMEDI)
University of Ireland Galway

Keynote

Frank Barry currently serves as a senior scientist with the Arthritis Program, University Health Network in Toronto. He also serves as a professor of Cellular Therapy at the Regenerative Medicine Institute, National University of Ireland Galway. He directs a large group of researchers who focus on the development of new repair strategies in stem cell therapy and gene therapy in Orthopaedics. Previously, he was Director of Arthritis Research at Osiris Therapeutics in Baltimore, Maryland, and a research fellow at Shriners Hospital for Children, in Tampa, Florida.

He has contributed to the fields of tissue engineering and regenerative medicine by developing innovative and successful cellular therapies for the treatment of acute joint injury and arthritic disease. Barry’s team has generated of a large body of new data in ground-breaking preclinical studies, which has led to the first phase of clinical testing of mesenchymal stem cells in clinical trials for joint injury.

In a career that has spanned both industry and academic research, Barry has been a driver in the development of cellular therapy as a biological repair strategy. It is his belief that the application of new technologies in regenerative medicine, including cellular therapy, gene therapy, growth factor augmentation, implantable scaffolds and nanomaterials, will have a profound impact in orthopaedics. Barry was the recipient of the 2012 Marshall Urist Award for excellence in tissue regeneration research from the Orthopaedic Research Society.

Keynote Presentation: Cell Strategies for Arthritic Disease

Johnny Huard

Johnny Huard, PhD
Johnny Huard, PhD, Director, IMM Center for Tissue Engineering and Aging Research, Distinguished Chair for Orthopaedic Research, University of Texas Health Science Center at Houston

Keynote

A native of Canada, Dr. Johnny Huard is currently a professor in the Department of Orthopedic Surgery at the University of Texas Health Science Center at Houston in the McGovern Medical School. Huard is also the chief scientific officer and director of the Center for Regenerative Sports Medicine at the Steadman Philippon Research Institute in Vail, Colorado.

Huard was awarded the 2018 Kappa Delta Ann Doner Vaughan Award by the American Academy of Orthopaedic Surgeons. This lifetime achievement award is a culmination of his 20-plus years of scientific research related to the musculoskeletal system. In 2004, Huard, as a junior faculty member, was the recipient of the esteemed Kappa Delta Young Investigator award.

Huard is internationally recognized for his cutting-edge science in the field of stem cell research. He and his team have received national and international recognition, and the technologies they have developed, have been licensed to industry. He has extensive expertise in gene therapy, tissue engineering, and regenerative medicine – all based on the use of adult muscle-derived stem cells. His current major research interests include: aging, skeletal muscle stem cell isolation and characterization, bone and articular cartilage regeneration through stem cell transplantation, cardiac and skeletal muscle injury repair, regeneration, and fibrosis prevention; and peripheral nerve regeneration using muscle-derived stem cells.

In his current faculty role, Huard leads a laboratory of over 40 individuals in Houston and Vail, including medical, graduate and undergraduate students, post-doctoral researchers, basic science faculty and staff, clinical research fellows, and technical and administrative staff. Huard’s funding to support his research program comes from the National Institutes of Health, Department of Defense, charitable foundations, private industry, and philanthropy.

Keynote Presentation: Stem Cells and Aging

Lynne Boxer

Lynne Boxer, DVM
Center for Veterinary Medicine (CVM)
US Food and Drug Administration

Dr. Lynne Boxer obtained her veterinary degree from the Virginia-Maryland Regional College of Veterinary Medicine. After graduation, Boxer practiced equine medicine in an ambulatory practice in California before joining FDA’s Center for Veterinary Medicine. Boxer is a veterinary medical officer in the Office of New Animal Drug Evaluation. In her current role, she is the center lead for cell-based products and develops regulatory and review policy and procedures for these products. Boxer also conducts educational outreach for the FDA.

Presentation Topic: Word from the Government: Regulation of Stem Cell Therapeutics

Ryan Crisman

Ryan Crisman, PhD
Director of Cell Processing
Interim Facility Director
Gates Center for Regenerative Medicine

Ryan Crisman, director of Cell Processing and interim facility director at the Gates Center for Regenerative Medicine, has a strong background in biotechnology and bringing products to market. Prior to arriving on the University of Colorado Anschutz Medical Campus, Ryan was associate director and Chemistry and Manufacturing Controls lead of JCAR017,  a chimeric antigen receptor (CAR) T-cell therapy, for Juno Therapeutics in Seattle, which licensed in CAR-T cell technology developed by Dr. Terry J. Fry, one of the leading cancer researchers in the country. Crisman received his doctorate in chemical and biological engineering from the University of Colorado Boulder.

Presentation Topic: Manufacturing for Cutting Edge Research: Bridging the Lab to the Clinic

Laura Damioli

Laura Damioli, MD
Assistant Professor
Medicine-Infectious Disease
UC Denver – Anschutz Medical Campus
Laura.Damioli@ucdenver.edu

Dr. Damioli is an infectious Disease specialist at the University of Colorado. Originally from Atlanta, she completed her training in internal medicine at the Ochsner Clinic Foundation in New Orleans, followed by a fellowship in infectious diseases at Louisiana State University. Throughout her career, she has developed a special interest in orthopaedic infections, and has noted the difficulties in treating such infections when hardware is involved. Hardware-associated infections are difficult to treat because bacteria form a biofilm that coats the hardware. This bacteria can currently only be eradicated by removing the hardware. Based on the work of CSU veterinarians Dr. Valerie Johnson and her colleague Dr. Steven Dow, Damioli is currently working on a clinical trial using pre-activated mesenchymal stem cells to treat orthopaedic hardware-associated infections in human patients. This mesenchymal stem cells treatment, if effective in humans, would enable treatment of orthoapedic infections without the need for hardware removal.

Presentation Topic: Stem Cell Therapies as Adjunctive Treatment for Orthopaedic Infections

Steven Dow

Steven Dow, DVM, PhD
Clinical Sciences
Colorado State University
Steven.Dow@colostate.edu

Dr. Dow received his Doctor of Veterinary Medicine degree from the University of Georgia and completed a residency in small animal internal medicine at Colorado State University. He then completed a PhD program in comparative pathology in the laboratory of University Distinguished Professor Dr. Ed Hoover at Colorado State University. After that, Dow completed a post-doctoral fellowship at National Jewish in Denver, where he worked in the laboratory of Dr. Terry Potter, before joining the faculty of the Department of Clinical Sciences at CSU in 2002. He is currently a professor of immunology in the Department of Clinical Sciences and the director of the Center for Immune & Regenerative Medicine at CSU.

Presentation Topic: New Insights into the Treatment of Childhood Cancer Gained from Clinical Trials in Dogs

Nicole Ehrhart

Nicole Ehrhart, VMD, Diplomate ACVS
Professor
Surgical Oncology
Ross M. Wilkins, MS Limb Preservation University Chair in Musculoskeletal Biology and Oncology
Nicole.Ehrhart@colostate.edu

Dr. Ehrhart is a Professor of Surgical Oncology and Co-Director of the Musculoskeletal Oncology Laboratory. Ehrhart has a strong translational research focus centered on orthopaedic oncology. Specifically, she is involved in research involving bone healing following large resection or loss of bone and the manner in which cancer therapies inhibit bone healing. Current work includes use of genetically modified mesenchymal stem cells to improve allograft revitalization and bone healing in cancer patients. Ehrhart’s expertise includes the use of animal models in orthopaedic research. The over-arching goal of her research is limb preservation.

Ehrhart runs the musculoskeletal oncology laboratory, which is focused on reconstructing bone to save the legs of dogs who have cancer.  Ehrhart collaborates with pediatric oncologists, whose aim is to preserve limb loss in children with cancer. Together, these teams are exploring ways to enhance bone healing in cancer patients who are undergoing anticancer therapy. Ehrhart is also conducting research using gene therapy to stimulate cells to make bone where they normally wouldn’t. She is also studying different kinds of endoprosthetics to help reconstruct large bone defects.

Presentation Topic: Limb Preservation: Hope for the Toughest Salvages Cases

David Frisbie

David Frisbie, DVM, PhD
Department Clinical Sciences
Colorado State University
David.Frisbie@colostate.edu

Dr. Frisbie began his professional career after obtaining both a bachelor’s degree in biochemistry and a Doctor of Veterinary Medicine from the University of Wisconsin. He completed a surgical internship at Cornell University, where he began his research in joint disease. After completing his internship, Frisbie came to Colorado State University, where he completed a surgical residency in Large Animal Surgery and a master’s degree in Joint Pathobiology. He then began his work on a novel way to treat joint disease using gene therapy, which was the focus of his PhD.

Frisbie is a professor of Equine Surgery at Colorado State University’s Equine Orthopaedic Research Center and the director of research. He is a partner in Equine Sports Medicine, LLC, specializing in orthopaedics and sports medicine. Frisbie was recently named director of operations for the C. Wayne McIlwraith Translational Medicine Institute, which is due to open in November, 2018. In addition, he is a diplomate of the American College of Veterinary Surgeons and a diplomate of the American College of Veterinary Sports Medicine and Rehabilitation.

Frisbie specializes in orthopaedic research, intra-articular therapeutics, new methods of cartilage repair, equine lameness, orthopaedic surgery and gene therapy.

Presentation Topic: The New Frontier of Orthopaedic Surgery: Regenerative Medicine

Terry Fry

Terry Fry, MD
Director of Cancer Immunotherapy
Co-Director of Human Immunology
UC Denver – Anschutz Medical Campus

Before joining the Anschutz Medical Campus community, Dr. Fry was a tenure-track investigator at the Pediatric Oncology Branch of the National Cancer Institute. Prior to that, he served as chief of Blood and Marrow Transplantation at Children’s National Medical Center, a position he held until 2010 when he returned to the Pediatric Oncology Branch as head of the Hematologic Malignancies Section. Fry received his medical degree from Georgetown University in 1992. After completing a pediatric residency at Georgetown in 1995, he served as chief pediatric resident. Fry undertook fellowship training in pediatric hematology/oncology at Johns Hopkins University and established a research program focused on the immunology of stem cell transplantation as a platform for cancer immunotherapy.

Fry was among the first scientists to investigate the potential to insert modified genes into a child’s own T-cells to target CD19, a surface protein found on nearly all cells affected by acute lymphoblastic leukemia. The first product using this technology, called chimeric antigen T-cell (CAR-T cells), was approved by the FDA for pediatric use in August 2017 and achieved an astonishing 80 percent remission rate in children with highly refractory leukemia resistant to all other therapies, including conventional bone marrow transplant. Fry has led several major studies to improve treatments for people with leukemia. In November, the journal Nature Medicine published an article that outlined a new treatment that genetically alters a patient’s cells to fight cancer. Fry is the first author of the study. His work has been highlighted in the Discovery documentary First in Human, which aired last August, and in a recent New York Times article and Washington Post feature.

Presentation Topic: New Insights into the Treatment of Childhood Cancer Gained from Clinical Trials in Dogs

Max Gomez

Max Gomez, PhD
Emmy award winning medical correspondent

The recipient of numerous journalism awards, Dr. Max Gomez has received seven New York Emmy Awards, two Philadelphia Emmys, a UPI honor for Best Documentary for a report on AIDS, and an Excellence in Time of Crisis Award from New York City after September 11. He was also named the American Health Foundation’s Man of the Year and was a NASA Journalist-In-Space semi-finalist in 1986.

Gomez has served on the national board of directors for the American Heart Association, the Princeton Alumni Weekly and the Partnership for After School Education. He also mentors undergraduate journalism and medical students and physicians who are interested in medical journalism.

Gomez is the co-author of “The Healing Cell: How the Greatest Revolution in Medical History is Changing Your Life”, a primer on the numerous uses of adult stem cells in treating and curing diseases. It includes an introductory message from Pope Benedict XVI.

A native of Havana, Cuba, Gomez speaks Spanish. He graduated cum laude from Princeton University, with a PhD from the Wake Forest University School of Medicine. He was also a NIH Postdoctoral Fellow at New York’s Rockefeller University. Gomez currently resides in New York City.

Presentation Topic: The Future of Regenerative Medicine

Laurie Goodrich

Laurie Goodrich, DVM PhD
Associate Professor
Clinical Sciences
Colorado State University
Laurie.Goodrich@colostate.edu

Dr. Laurie Goodrich is an associate professor of orthopaedics in the Department of Clinical Sciences. Her laboratory studies new approaches to bone and joint healing in equine athletes, and employs both gene therapy and stem cell therapy. Ongoing studies include using adeno-associated viral vectors to deliver growth factors and anti-inflammatory molecules important in cartilage and bone healing. Goodrich has utilized mesenchymal stem cells and platelet rich plasma to improve cartilage repair. Further studies utilizing gene therapy combined with stem cell therapies to improve musculoskeletal repair are currently underway.

Presentation Topic: Horses Translating to People

Valerie Johnson

Valerie Johnson, DVM
Clinical Sciences
Colorado State University
Valerie.Johnson@colostate.edu

Dr. Johnson is a critical care veterinarian and postdoctoral research fellow at the James L. Voss Veterinary Teaching Hospital at Colorado State University. She has a strong interest in exotic species and wildlife, and also works at the Wild Animal Sanctuary in Keenesburg, Colorado, as a staff veterinarian.

Johnson has conducted research in regenerative medicine with mesenchymal stem cells as a therapeutic modality for various disease processes, including multidrug resistant infections, immune mediated disease and arthritis. She has worked with animal models and canine clinical trials to elucidate the mechanisms by which these cells exert a therapeutic effect. A recent clinical trial in dogs using pre-activated mesenchymal stem cells to treat infections that had not responded to conventional therapy had a resolution of infection in 80 percent of patients and improvement in 100 percent.

Johnson was also involved in another clinical trial in dogs studying dogs with severe arthritis. Clinicians used force plate gait analysis and examined joint fluid to evaluate the dog’s pain before and after intravenous mesenchymal stem cells injections. No adverse effects were noted in any animal and all dogs were reported to improve substantially even after withdrawal from nonsteroidal anti-inflammatory medications for the six-month period of observation (publication in progress).

Exotic animals in protected environments pose a challenge in the management of chronic age-related degenerative diseases. Medications are not well tolerated by some species, and dosing and administration can be a challenge in the larger species. Regenerative medicine is a promising new avenue for treatment of these conditions. Johnson has safely treated several species with cells grown in the laboratory, including a polar bear, mountain lion, tiger, wolf, coyote, giraffe, tiger, leopard and elephant.

Johnson is interested in advancing medical care for species which currently have limited therapeutic options, and investigating the potential of regenerative medicine in these animals. Her experience in regenerative medicine and working with cells from multiple species puts her in a unique position to develop more efficient and effective methods for treating these valuable animals.

Presentation Topic: Stem Cell Therapies as Adjunctive Treatment for Orthopaedic Infections, Lions, Tigers, Bears, and Stem Cells!

Wei Liang

Wei Liang, PhD
Center for Biologics Evaluation and Research (CBER)
US Food and Drug Administration

Dr. Liang is a pharmacology/toxicology reviewer in the Office of Tissues and Advanced Therapies in the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. She joined the Office of Tissues and Advanced Therapies in 2006. Her primary focus is the review of preclinical testing programs, including in vitro and in vivo animal studies that are intended to support the conduct of clinical studies of cellular and gene therapy-based products, as well as some blood products for various indications.

Presentation Topic: Word from the Government: Regulation of Stem Cell Therapeutics

wayne mcilwraith

Wayne McIlwraith, DVM, PhD, Dipl ACVS, Dipl ACVSMR
University Distinguished Professor
Director, Orthopaedic Research Center
Equine Surgery, Orthopaedics
Director, Musculoskeletal Research Program
Orthopaedic Research Center
Colorado State University
Wayne.McIlwraith@colostate.edu

Dr. McIlwraith obtained his veterinary degree from Massey University, New Zealand, and subsequently was in practice in New Zealand and the United Kingdom, followed by an internship at the University of Guelph in Canada, and a surgical residency at Purdue University. He also obtained master’s and doctoral degrees from Purdue University. Since 1979, he has been a faculty member at Colorado State University and is currently a University Distinguished Professor, holds the Barbara Cox Anthony University Endowed Chair in Orthopaedics and is the Founding Director of the Orthopaedic Research Center.

McIlwraith has a referral equine orthopaedic surgical practice based in Southern California and is a consultant and surgeon for clients in the United States and Ireland, England, France and New Zealand.

His research interests focus on equine orthopaedic surgery and translational joint disease research, including novel treatments for osteoarthritis and articular cartilage repair, mesenchymal stem cell therapies and early diagnosis of osteoarthritis and pre-fracture disease using imaging and fluid biomarkers. He has authored six textbooks, 450 scientific publications and textbook chapters and given over 650 scientific presentations, seminars and workshops.

Honors include doctoral degrees (honoris causa) from the University of Vienna, Purdue University, Massey University, the University of Turin and the University of London, the Founders Award for Lifetime Achievement from American College of Veterinary Surgeons, the Frank Milne Lecturer at American Association of Equine Practitioners and the John Hickman Award for Equine Orthopaedics from the British Equine Veterinary Association.

McIlwraith was also inducted into the international Equine Research Hall of Fame and is the recipient of the Markowitz Award from the Academy of Surgical Research and the Marshall R. Urist MD Award for Excellence in Tissue Regeneration Research from the Orthopaedic Research Society.

Presentation Topic: An Equine-to-Human Journey in Muscoloskeletal Translational Medicine

Karin Payne

Karin A. Payne, PhD
Assistant Professor
Department of Orthopaedics
UC Denver – Anschutz Medical Campus
Karin.Payne@ucdenver.edu

Dr. Payne is an assistant professor of Orthopaedics at the University of Colorado Anschutz Medical Campus and a faculty member of the Gates Center for Regenerative Medicine. She directs the Regenerative Orthopaedics Laboratory at CU Anschutz and her research program focuses on the development of functional regenerative medicine approaches to treat growth plate cartilage injuries resulting from pediatric fractures by using stem cells, growth factor augmented biomaterials and 3D printed implants.

Other active projects in the laboratory include revitalizing bone allografts with stem cells to enhance bone formation in spinal fusion, and investigating stem cell- and biomaterial-based approaches for articular cartilage regeneration. Her research is funded by the National Institutes of Health, the Musculoskeletal Transplant Foundation, the Pediatric Orthopaedic Society of North America, as well as Children’s Hospital Colorado and the University of Colorado School of Medicine.

She received her PhD in Bioengineering from the University of Pittsburgh, where she studied muscle-derived stem cells and their application in bone and articular cartilage regeneration. Her postdoctoral work investigated how donor sex and age affect the chondrogenic ability of human bone marrow-derived mesenchymal stem cells.

Presentation Topic: The New Frontier of Orthopaedic Surgery: Regenerative Medicine

Michael S. Perry, Zoobiquity Conference speaker, Chief Executive Officer for Avita Medical

Michael S. Perry, DVM, PhD
Chief Executive Officer for Avita Medical, and Director at Gamida Cell Ltd. and Bioscience Managers Pty. Ltd

Dr. Mike Perry currently serves as CEO for Avita Medical, a regenerative medicine company, and is a director at Gamida Cell Ltd. and Bioscience Managers Pty. Ltd. From 2012 to 2015, he was the chief scientific officer for Novartis’ Cell & Gene Therapy Unit. Perry was a venture partner with Bay City Capital from 2004 to 2012; during this time, he concurrently served as president and chief medical officer of Poniard Pharmaceuticals and chief development officer of VIA Pharmaceuticals.

Perry has served as chairman and CEO of Extropy Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, and as president and CEO of Pharsight Corporation, a publicly held Bayesian modeling and simulation consulting firm. He has also served as global head of Research and Development for Baxter Healthcare, and as president and CEO of SyStemix Inc. and Genetic Therapy Inc., both wholly owned subsidiaries of Novartis Corporation. Perry has also served as vice president of Regulatory Affairs for Novartis Pharma.

Perry earned degrees in veterinary medicine and surgery, biomedical pharmacology (PhD) and physics (Hon B.Sc.) from the University of Guelph in Ontario, Canada. He is a fellow of the Royal College of Veterinary Surgeons and a graduate of the International Management Program at Harvard Business School. He currently serves as an independent Director of three publicly traded healthcare companies and as adjunct professor of Regenerative Medicine and Stem Cell Biology in the Gates Center for Regenerative Medicine at the University of Colorado School of Medicine in Denver.

Presentation Topic: The Future of Regenerative Medicine

Dennis Roop, speaker at Zoobiquity Conference, Professor of Dermatology, University of Colorado Denver, Charles C. Gates Chair of Regenerative Medicine and Stem Cell Biology

Dennis Roop, PhD
Professor of Dermatology
UC Denver – Anschutz Medical Campus

Dennis R. Roop is professor of Dermatology, holds the Charles C. Gates Chair in Regenerative Medicine and Stem Cell Biology, and is director of the Regenerative Medicine and Stem Cell Biology Program at the University of Colorado’s Anschutz Medical Campus in Aurora. Prior to joining CU in 2006, Roop was professor of molecular and cellular biology at the Baylor College of Medicine in Houston. In 2001, he received the Michael E. DeBakey Award for Excellence in Research, the medical school’s highest award.

Originally from Jonesville, Virginia, Roop graduated from Berea College in 1969 with a degree in biology. He received his MS and PhD degrees from the University of Tennessee, Knoxville, and completed post-doctoral work at Baylor College of Medicine.

The Gates Family Fund donated $6 million to start CU’s Charles C. Gates Program in Regenerative Medicine and Stem Cell Biology. A year later they gave The Children’s Hospital and the University of Colorado School of Medicine another $5 million to help continue translating laboratory stem-cell science into help for patients of all ages with a variety of inherited and acquired illnesses. Roop now directs a team of about 26 people, including seven faculty members, in a 10,000-square-foot university research laboratory.

Presentation Topic: Advances in the Treatment of Ehlers-Danlos: And the Potential Role of Small Animals as a Clinical Model

Jennifer Schissler

Jennifer Schissler, DVM, MS, DACVD
Assistant Professor of Dermatology
Clinical Sciences
Colorado State University
Jennifer.Schissler@colostate.edu

Jennifer Schissler is a Colorado native and an assistant professor in the Department of Clinical Sciences at Colorado State University. She graduated Summa Cum Laude from CSU’s Doctor of Veterinary Medicine Program in 2005. After completing a one-year rotating internship in small animal medicine and surgery at Wheat Ridge Animal Hospital in Wheat Ridge, Colorado, she completed a combined master’s degree and dermatology residency at The Ohio State University in Columbus, Ohio. Schissler’s medical interests include cutaneous infectious disease, antimicrobial resistance, infection control practices, clinical immunology and otology. She became a diplomate of the American College of Veterinary Dermatology in 2009.

Presentation Topic: Advances in the Treatment of Ehlers-Danlos: And the Potential Role of Small Animals as a Clinical Model

Jason Stoneback

Jason Stoneback, MD
Assistant Professor
Department of Orthopaedics
UC Denver – Anschutz Medical Campus
Jason.Stoneback@ucdenver.com

Jason Stoneback, MD, is an Assistant Professor in the Department of Orthopaedics at the University of Colorado, School of Medicine. He is director of the Multidisciplinary Limb Restoration Program and director of Orthopaedic Trauma and Fracture Surgery at University of Colorado Hospital. Dr. Stoneback completed his Orthopaedic Surgery Residency at the University of Colorado Denver. He completed his fellowship training in Orthopaedic Traumatology at Saint Louis University in St. Louis, Missouri. He specializes in the treatment of simple and complex fractures, non-unions, malunions, osteomyelitis, orthopaedic infections, limb-length discrepancies, deformity correction and post-traumatic limb salvage and restoration. His goals are to use an interdisciplinary approach to optimize health outcome who lose or at risk of losing a limb. This interdisciplinary approach, involving comprehensive orthopaedic, vascular, wound, and rehabilitative care, is serving a growing number of patients with complex extremity injuries. He has always been intrigued and inspired by the connection between form and function. He is highly motivated to provide patients with real options – often when all other choices have been exhausted.

Presentation Topic: Limb Preservation: Hope for the Toughest Salvage Cases

Tracy Webb

Tracy Webb, DVM, PhD
Clinical Sciences
Colorado State University
Tracy.Webb@colostate.edu

Dr. Tracy Webb received her DVM degree from The Ohio State University and then completed a small animal medicine and surgery internship followed by an emergency and critical care residency at Angell Animal Medical Center.  Webb then moved to Colorado where she received a PhD in Immunology/Pathology and remained at Colorado State University in a Research Scientist role as well as performing clinical work. She has been involved in many different projects as she strives to make a positive difference in the field of veterinary medicine. With over 10 years of research effort in regenerative medicine, Webb has performed many in vitro studies as well as clinical trials looking at a variety of disease processes (chronic kidney disease, asthma, chronic enteropathy/inflammatory bowel disease/other gastrointestinal disease, osteoarthritis, infection management) in a number of animal species (domestic cats, dogs, ferrets, tigers).  Webb has been on the Board of Directors of the North American Veterinary Regenerative Medicine Association for the past several years. She has more recently been involved in the COHA Communication and Collaboration subcommittee and in efforts to encourage and support quality clinical trials and the use of natural animal models to accelerate translational research.

Presentation Topic: Taming the Cat: MSC for Inflammatory Diseases in Cats